Mineralys Therapeutics Inc’s recent filing unveils that its Chief Executive Officer Congleton Jon unloaded Company’s shares for reported $0.23 million on Jul 11 ’25. In the deal valued at $14.51 per share,15,884 shares were sold. As a result of this transaction, Congleton Jon now holds 846,405 shares worth roughly $12.04 million.
Then, Levy Adam Scott sold 10,758 shares, generating $155,454 in total proceeds. Upon selling the shares at $14.45, the CFO and Secretary now owns 206,612 shares.
Before that, Rodman David Malcom sold 11,366 shares. Mineralys Therapeutics Inc shares valued at $165,879 were divested by the Chief Medical Officer at a price of $14.59 per share. As a result of the transaction, Rodman David Malcom now holds 97,907 shares, worth roughly $1.39 million.
Jefferies initiated its Mineralys Therapeutics Inc [MLYS] rating to a Hold in a research note published on June 11, 2025; the price target was $15. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early July with a ‘”a Buy”‘ rating. Goldman began covering MLYS with “Buy” recommendation on April 02, 2024. Wells Fargo started covering the stock on March 07, 2023. It rated MLYS as “an Overweight”.
Price Performance Review of MLYS
On Friday, Mineralys Therapeutics Inc [NASDAQ:MLYS] saw its stock fall -0.77% to $14.23. Over the last five days, the stock has lost -1.79%. Mineralys Therapeutics Inc shares have fallen nearly -2.40% since the year began. Nevertheless, the stocks have risen 15.60% over the past one year. While a 52-week high of $18.38 was reached on 03/19/25, a 52-week low of $8.24 was recorded on 02/25/25.
Levels Of Support And Resistance For MLYS Stock
The 24-hour chart illustrates a support level at 14.00, which if violated will result in even more drops to 13.77. On the upside, there is a resistance level at 14.60. A further resistance level may holdings at 14.97.
How much short interest is there in Mineralys Therapeutics Inc?
A steep rise in short interest was recorded in Mineralys Therapeutics Inc stocks on 2025-06-13, dropping by -1.04 million shares to a total of 6.17 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 7.21 million shares. There was a decline of -16.83%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 07, 2023 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $45 price target.
